Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort

BACKGROUND: Efficacious, well-tolerated, direct antiviral agents have drastically changed the prognosis of hepatitis C virus (HCV) disease, but real-world data for oral treatments are limited in key populations such as HIV/HCV coinfection with advanced liver disease. Daclatasvir (DCV) efficacy and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacombe, Karine, Fontaine, Hélène, Dhiver, Catherine, Metivier, Sophie, Rosenthal, Eric, Antonini, Teresa, Valantin, Marc Antoine, Miailhes, Patrick, Harent, Stanislas, Batisse, Dominique, Pageaux, Georges-Philippe, Chas, Julie, Aumaitre, Hugues, Dominguez, Stephanie, Allegre, Thierry, Lafeuillade, Alain, Billaud, Eric, De Truchis, Pierre, Perre, Philippe, Leroy, Vincent, De Ledinghen, Victor, Sogni, Philippe, Dabis, François, Zhao, Yue, Filipovics, Anne, Fedchuk, Larysa, Akremi, Raoudha, Bennai, Yacia, Salmon Ceron, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389585/
https://www.ncbi.nlm.nih.gov/pubmed/28272163
http://dx.doi.org/10.1097/QAI.0000000000001342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389585/
https://www.ncbi.nlm.nih.gov/pubmed/28272163
http://dx.doi.org/10.1097/QAI.0000000000001342

Ejemplares similares